# The Benson Complex Figure Test for the Differential Diagnosis of Dementias

**Authors:** Marina Papadogiani, Theodoros Fasilis, Akyllina Despoti, Vasiliki Kamtsadeli, Maria Hantzopoulou, Niki Tsinia, Evdoxia Lykou, Lina Chatziantoniou, Dimitrios Chousos, Kostas Siarkos, John D. Papatriantafyllou

PMC · DOI: 10.3390/neurosci7020038 · 2026-03-20

## TL;DR

The Benson Complex Figure Test helps distinguish between different types of dementia, especially Alzheimer's disease, by assessing visuospatial and memory skills.

## Contribution

The study demonstrates the BCFT's ability to differentiate dementia subtypes with a simpler design than traditional tests.

## Key findings

- CBD patients had significantly lower copy scores compared to those with ADD.
- FTD-NFV showed superior memory scores compared to other dementia subtypes.
- Poor BCFT recognition was strongly linked to ADD, FTD-BV, and PDD.

## Abstract

The Benson Complex Figure Test (BCFT) is a neuropsychological tool designed to assess visuospatial construction and visual memory with lower complexity than traditional tests. This study evaluated its ability to differentiate between major dementia subtypes. In a retrospective cross-sectional analysis of 1428 participants from a Greek third-age day center (healthy participants [Controls]; patients diagnosed with Alzheimer’s disease dementia [ADD], Lewy body dementia [LBD], Frontotemporal dementia [FTD: behavioral variant (BV), non-fluent variant (NFV), semantic variant (SV)], Corticobasal dementia [CBD], Parkinson’s disease dementia [PDD], and mixed Cardiovascular dementia with Alzheimer’s disease [CVD/AD]), all participants completed the BCFT and the Mini-Mental State Examination (MMSE). Multinomial logistic regression, adjusted for age, sex, and education, revealed distinct BCFT profiles across dementia subtypes. Patients with CBD showed significantly lower copy scores than those with ADD (p = 0.006). The FTD-NFV group exhibited superior memory scores compared to all other dementia subtypes (p < 0.001). Poorer BCFT recognition performance was strongly associated with diagnoses of ADD (OR = 0.39, p = 0.012), FTD-BV (OR = 0.22, p = 0.025), and PDD (OR = 0.26, p < 0.001). Classification accuracy was highest for controls and ADD (sensitivity > 89%) but low for rarer subtypes (<25%), partly reflecting sample size limitations. In conclusion, the BCFT captures distinct visuospatial and memory profiles across dementia syndromes, supporting its potential utility in differential diagnosis, particularly for common subtypes such as ADD. Its simpler design may facilitate assessment in older adults, although validation in larger and more balanced cohorts is required for rarer dementias.

## Linked entities

- **Diseases:** Lewy body dementia (MONDO:0007488), Frontotemporal dementia (MONDO:0010857), Alzheimer’s disease (MONDO:0004975)

## Full-text entities

- **Genes:** MAPT (microtubule associated protein tau) [NCBI Gene 4137] {aka DDPAC, FTD1, FTDP-17, MAPTL, MSTD, MTBT1}
- **Diseases:** executive dysfunction (MESH:D006331), atrophy (MESH:D001284), vision or hearing loss (MESH:D054062), visual-spatial and executive deficits (OMIM:313000), CBD (OMIM:303800), visual impairments (MESH:D014786), fluency (MESH:D013064), schizophrenia (MESH:D012559), CBD (MESH:D000088282), basal ganglia dysfunction (MESH:D001480), sensory impairments (MESH:D012678), Visuospatial impairment (MESH:D000377), stroke (MESH:D020521), impaired syntax (MESH:D060825), Dementia (MESH:D003704), BCFT (MESH:D013736), frontal white matter tract abnormalities (MESH:D056784), injury to (MESH:D014947), visual hallucinations (MESH:D006212), SV (MESH:D002303), LBD (MESH:D020192), ischemic injury (MESH:D017202), PDD (MESH:D003966), occipital cortex hypometabolism (MESH:D006259), copy and memory deficits (MESH:D008569), traumatic brain injury (MESH:D000070642), neurodegenerative diseases (MESH:D019636), attention problems (MESH:D001289), major depression (MESH:D003865), primary progressive aphasia (MESH:D018888), apraxia (MESH:D001072), language impairments (MESH:D007806), LBD (MESH:D020961), recognition deficits (MESH:D020238), deficits (MESH:D009461), CVD (MESH:D002318), FTD (MESH:D057180), AD (MESH:D000544), psychiatric disorders (MESH:D001523), cognitive decline (MESH:D003072), PD (MESH:D010300), cortical dysfunction (MESH:D054220)
- **Chemicals:** CBD (-)
- **Species:** Homo sapiens (human, species) [taxon 9606]

---
Source: https://tomesphere.com/paper/PMC13010747